Cadrenal Therapeutics appoints Robert Lisicki to Board of Directors

Cadrenal Therapeutics, Inc.

Robert Lisicki appointed as Class II director effective July 23, 2023; Board expanded from four to five seats.
Lisicki brings over 25 years pharma experience, including CCO at Arena Pharmaceuticals through its $6.7B sale to Pfizer.
He will receive $35,000 annual fee and 75,000 stock options vesting 1/3 on Aug 1, 2024 then monthly over 24 months.
Lisicki also joins Compensation and Nominating/Governance Committees.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Lisicki

Class II Director

CVKD · Cadrenal Therapeutics, Inc.

Effective: 2023-07-23
Filed: July 24, 2023, 7:59 PM ET

appointed Robert Lisicki to serve as a Class II director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Lisicki was appointed as Class II Director at Cadrenal Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed Robert Lisicki to serve as a Class II director of the Company

View on SEC.gov

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-059049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.